Edit: Ahmed Al-Kumi

The British Health Security Agency announced today, based on preliminary results of a realistic study, that enhanced doses of corona vaccine are being administered. COVID-19

provides 70-75% protection from the light symptoms of the new mutant version of the Corona omicron virus, and these results represent some of the earliest data from outside laboratory studies on protection against omicron mutants, which show reduced immune activity against omicron.

Early data from the real-life study indicate that while the omicron mutant is largely capable of avoiding protection from the minor symptoms of its two doses, enhanced doses restore some of this protection.

Dr. Mary Ramsey, head of vaccination at the British Health Security Agency, said that "care needs to be taken in dealing with these early estimates, but suggests that the risk of omicron a few months after the second dose is greater than delta mutant," expecting protection from severe symptoms to remain greater.

The head of vaccination at the British Health Security Agency added, "Data indicate that this risk declines significantly after the enhanced dose, and I therefore urge everyone to take the enhanced doses if they are eligible."

In an analysis of 581 people confirmed to be infected with omicron, it was found that the enhanced dose of the Pfizer vaccine protected about 70% of symptomatic infections in those who initially received the AstraZenia vaccine, and about 75% for those who received the Pfizer dose.

For his part, American pharmaceutical company Pfizer CEO Albert Burla said that a fourth dose of its Corona vaccine might eventually be required, amidst fears of the Omicron mutant, and he had previously said that a fourth dose might be needed 12 months after the third dose, but with Omicron this timetable might need to be increased.

Pfizer's remarks follow his company's announcement that "three doses appear to provide good protection."

Earlier, the World Health Organization (WHO) announced that there were no indications that the new omicron mutant from the corona virus, recently discovered in South Africa, was causing more disease, compared to the delta mutant, and global health asserted that "there is no reason to doubt the effectiveness of current anti-corona vaccines in front of the omicron mutant."